Literature DB >> 1531593

Regional distribution and in vivo binding of the atypical antipsychotic drug remoxipride. A biochemical and autoradiographic analysis in the rat brain.

C Köhler1, A C Radesäter, G Karlsson-Boethius, B Bryske, M Widman.   

Abstract

The regional brain distribution and binding of the antipsychotic benzamide drug remoxipride was studied in the male rat. After i.v. injections of 3H-remoxipride (1 mumol.kg-1) more than 85% of the radioactivity was identified as authentic remoxipride in brain by using reversed-phase liquid chromatography. Autoradiographic and spectroscopic analysis showed that 3H-remoxipride was distributed relatively even in different brain areas, with exception of the following structures, which showed highest drug concentrations: the choroid plexus, septum, medial part of the caudate nucleus, different areas of the thalamus and hypothalamus situated close to the cerebral ventricles. A closer analysis of the autoradiograms showed a gradient of radioactivity extending from the cerebral ventricles to the deeper parts of the brain at 30 minutes after injections. After 60 minutes radioactivity was detected throughout all forebrain dopamine receptive areas. These findings suggest that remoxipride enters the cerebrospinal fluid (CSF) via the vascular bed of the choroid plexus and that it enters the brain interstitial fluid from the CSF. In the caudate nucleus, nucleus accumbens, olfactory tubercle and olfactory bulb 30-40% of the radioactivity was reduced by pretreatment with the dopamine D-2 selective drug raclopride. In addition, small, but significant, reductions (10-15%) of 3H-remoxipride derived radioactivity was found in the neocortex, hippocampus and the cerebellum, suggesting that remoxipride interacts with a D-2 receptor also in these cortical structures. Taken together, these studies show that after i.v. injections, 3H-remoxipride enters the brain primarily in unmetabolized form when given in doses that affect DA receptor mediated behaviours, that it distributes to most areas throughout the neuraxis and that it binds to D-2 receptors in different parts of the basal ganglia, neocortex, hippocampus and cerebellum.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1531593     DOI: 10.1007/bf01253110

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  24 in total

1.  Determination of remoxipride in plasma and urine by reversed-phase column liquid chromatography.

Authors:  L B Nilsson
Journal:  J Chromatogr       Date:  1990-03-16

2.  Classification of neuroleptic drugs according to their ability to inhibit apomorphine-induced locomotion and gnawing: evidence for two different mechanisms of action.

Authors:  T Ljungberg; U Ungerstedt
Journal:  Psychopharmacology (Berl)       Date:  1978-04-11       Impact factor: 4.530

Review 3.  Atypical antipsychotics--recent findings and new perspectives.

Authors:  J A Lowe; T F Seeger; F J Vinick
Journal:  Med Res Rev       Date:  1988 Oct-Dec       Impact factor: 12.944

4.  Comparison of the effects of substituted benzamides and standard neuroleptics on the binding of 3H-spiroperidol in the rat pituitary and striatum with in vivo effects on rat prolactin secretion.

Authors:  H Y Meltzer; R So; R J Miller; V S Fang
Journal:  Life Sci       Date:  1979-08-13       Impact factor: 5.037

5.  Septo-hippocampal system: target for substituted benzamides.

Authors:  S Bischoff; H Bittiger; A Delini-Stula; R Ortmann
Journal:  Eur J Pharmacol       Date:  1982-04-23       Impact factor: 4.432

6.  Autoradiographic study of 14C-sulpiride in monkey.

Authors:  A Benakis; J P Brown; P Benard
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Oct-Dec       Impact factor: 2.441

7.  Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.

Authors:  P A Janssen; C J Niemegeers; F Awouters; K H Schellekens; A A Megens; T F Meert
Journal:  J Pharmacol Exp Ther       Date:  1988-02       Impact factor: 4.030

Review 8.  Biochemical pharmacology of the atypical neuroleptic remoxipride.

Authors:  C Köhler; H Hall; O Magnusson; T Lewander; K Gustafsson
Journal:  Acta Psychiatr Scand Suppl       Date:  1990

Review 9.  Neuropharmacological and behavioural properties of remoxipride in the rat.

Authors:  S O Ogren; L Florvall; H Hall; O Magnusson; K Angeby-Möller
Journal:  Acta Psychiatr Scand Suppl       Date:  1990

10.  In vivo labelling of rat brain dopamine D-2 receptors. Stereoselective blockade by the D-2 antagonist raclopride and its enantiomer of 3H-spiperone, 3H-N,N-propylnorapomorphine and 3H-raclopride binding in the rat brain.

Authors:  C Köhler; G Karlsson-Boethius
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

View more
  6 in total

Review 1.  Enhanced prospects for drug delivery and brain targeting by the choroid plexus-CSF route.

Authors:  Conrad E Johanson; John A Duncan; Edward G Stopa; Andrew Baird
Journal:  Pharm Res       Date:  2005-07-22       Impact factor: 4.200

Review 2.  Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms?

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-06       Impact factor: 5.270

Review 3.  Biotransformation of post-clozapine antipsychotics: pharmacological implications.

Authors:  S Caccia
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

4.  Dopamine D2 blocking activity and plasma concentrations of remoxipride and its main metabolites in the rat.

Authors:  S O Ogren; J Lundström; L B Nilsson; M Widman
Journal:  J Neural Transm Gen Sect       Date:  1993

5.  Effects of typical and atypical antipsychotic drugs on two-way active avoidance. Relationship to DA receptor blocking profile.

Authors:  S O Ogren; T Archer
Journal:  Psychopharmacology (Berl)       Date:  1994-04       Impact factor: 4.530

6.  Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans.

Authors:  Jasper Stevens; Bart A Ploeger; Margareta Hammarlund-Udenaes; Gunilla Osswald; Piet H van der Graaf; Meindert Danhof; Elizabeth C M de Lange
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-07-12       Impact factor: 2.745

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.